<DOC>
	<DOCNO>NCT01209689</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate safety efficacy tocilizumab ( RoActemra/Actemra ) patient ankylose spondylitis ( AS ) inadequate response previous tumor necrosis factor ( TNF ) antagonist therapy . Patients randomize receive tocilizumab dose either 8 mg/kg 4 mg/kg intravenously ( iv ) placebo every 4 week 24 week . The double-blind treatment period follow open-label treatment tocilizumab 8 mg/kg iv every 4 week Week 104 patient . This study clinical development tocilizumab AS halt review 12-week data Study NA22823 , randomize double-blind , placebo-controlled study TNF antagonist naïve AS patient , fail demonstrate efficacy .</brief_summary>
	<brief_title>A Study Tocilizumab ( RoActemra/Actemra ) Patients With Ankylosing Spondylitis Who Have Had Inadequate Response Previous Tumor Necrosis Factor ( TNF ) Antagonist Therapy</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>Adult patient ≥ 18 year age . Ankylosing spondylitis define modified New York criterion ≥ 3 month prior baseline . Active disease screen baseline ( Bath Ankylosing Spondylitis Disease Activity Index [ BASDAI ] ≥ 4.0 , spinal pain visual analog scale [ VAS ] ≥ 40 ) . Inadequate response intolerant 1 previous nonsteroidal antiinflammatory drug ( NSAIDs ) . Inadequate response treatment etanercept , infliximab , adalimumab , golimumab inadequate efficacy . Tumor necrosis factor ( TNF ) antagonist therapy must discontinue least 8 week prior baseline ( etanercept 4 week ) . Traditional diseasemodifying antirheumatic drug ( DMARDs ) must withdraw least 4 week prior baseline ( methotrexate , sulfasalazine , hydroxychloroquine chloroquine may allow stable dose least 4 week prior baseline ) . Oral corticosteroid ( ≥ 10 mg/day prednisone equivalent ) NSAIDs/cyclooxygenase2 [ COX2 ] inhibitor must stable dose least 4 week prior baseline . Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month randomization . Total ankylosis spine ( determined investigator ) . Inflammatory rheumatic disease ankylose spondylitis . Active , acute uveitis baseline . Previous treatment tocilizumab . Intraarticular tendon injection parenteral corticosteroid within 4 week prior screen . History severe allergic anaphylactic reaction humanize murine monoclonal antibody . Active current history recurrent bacterial , viral , fungal , mycobacterial , infection . History currently active primary secondary immunodeficiency . Body weight &gt; 150 kg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>